Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...
To begin to close the equity gap in diabetes, we must commit to designing therapies that account for the practical realities ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to ...
Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...
Life science marketing is changing, and with it our need for personalised engagement strategies. While omnichannel marketing ...
"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...
The ACIP has been accused of cherry-picking data on side effects – attempting to perpetuate a debunked link between the shots ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, ...
It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major ...
The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback